Cutaneous Lupus Registry
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01266915|
Recruitment Status : Recruiting
First Posted : December 24, 2010
Last Update Posted : October 26, 2017
Approximately 1.4 million individuals in the United States have systemic lupus erythematosus, and about 85% of these individuals develop skin lesions at some point of their disease. Cutaneous lupus erythematosus represents the skin manifestations of systemic lupus erythematosus, and can appear in people with or without systemic lupus. It is a mentally, physically, and emotionally debilitating disease that affects both the quality of life and social well-being of those affected.
The cause of cutaneous lupus is not completely understood, but likely includes multiple factors from our genes and the environment. Multiple genetic studies with small numbers of cutaneous lupus patients have been performed to determine which genes are associated with cutaneous lupus. This study aims to accumulate even larger numbers of patients to confidently identify genes and the proteins they encode that could contribute greatly to the formation of cutaneous lupus. The discovery of these genes and proteins would help not only uncover how cutaneous lupus forms, but also improve our abilities to diagnose this disease and predict its course, and stimulate new drug development.
|Condition or disease|
The purpose of this study is to create a national registry of patients with cutaneous lupus patients in order to address many unknown questions about this disease. Specifically, we are interested in better understanding the causes of cutaneous lupus and improving our methods of diagnosis, prognosis, and management of this disease. We plan to use information from all patient sources, including medical histories, clinical information, laboratory data, and blood and skin samples in order to answer these questions.
Each study patient will be asked to complete a series of questionnaires, which, for example, will ask about cutaneous and/or systemic lupus history, past medical history, family history, quality of life, and sun protective habits. Patients will be also asked to donate blood and skin samples and undergo digital photography of affected areas. No treatments will be administered as part of this study, but all participants will be notified of clinical trials being conducted at UT Southwestern. This study is for the purpose of data collection only. Patients will be asked to be followed on an annual basis for five years.
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Molecular Studies on Cutaneous Lupus|
|Study Start Date :||January 2009|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2020|
Normal disease free (non lupus) subjects
Diseased group 1
Those subjects with systemic lupus erythematosus.
Diseased group 2
Subjects diagnosed with cutaneous lupus.
- Genes [ Time Frame: 5 years ]
- Proteins (ie. signaling proteins, autoantibodies) [ Time Frame: 5 years ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01266915
|Contact: Benjamin Chong, MD, MSCSfirstname.lastname@example.org|
|United States, Texas|
|University of Texas Southwestern Medical Center Dallas||Recruiting|
|Dallas, Texas, United States, 75390|
|Contact: Benjamin F Chong, MD, MSCS 214-648-3427 email@example.com|